Trending

biosimilars

Samsung Bioepis files Herceptin biosimilar in EU

Samsung Bioepis files Herceptin biosimilar in EU

South Korean firm trying to copy breast cancer blockbuster.

X

Samsung Bioepis files Herceptin biosimilar in EU

https://pharmaphorum.com/news/samsung-bioepis-files-herceptin-biosimilar-eu/

Amjevita, first Humira biosimilar approved – but no launch yet

Amjevita, first Humira biosimilar approved – but no launch yet

Amgen’s biosimilar is ready to go, but AbbVie believes it can delay until 2022

X

Amjevita, first Humira biosimilar approved – but no launch yet

https://pharmaphorum.com/news/humira-biosimilar-approved/

Biosimilar junket: Hospira took UK pharmacists to 5-star hotel in Croatia

Biosimilar junket: Hospira took UK pharmacists to 5-star hotel in Croatia

Hospira trip ruled to be disguised promotion

X

Biosimilar junket: Hospira took UK pharmacists to 5-star hotel in Croatia

https://pharmaphorum.com/news/biosimilar-junket-hospira-took-uk-pharmacists-5-star-hotel-croatia/

Bad news for Sanofi as biosimilar replaces Lantus

Bad news for Sanofi as biosimilar replaces Lantus

Pharmacy benefit firm axes Lantus, decision due on key combination therapy.

X

Bad news for Sanofi as biosimilar replaces Lantus

https://pharmaphorum.com/news/sanofi-facing-day-reckoning-us/

Biosimilar switching not suitable for all patients

Biosimilar switching not suitable for all patients

Antibodies against originator will also target biosimilar.

X

Biosimilar switching not suitable for all patients

https://pharmaphorum.com/news/biosimilar-switching-not-suitable-patients/

Biogen eyeing big-selling biosimilars as MS drug fails

Biogen eyeing big-selling biosimilars as MS drug fails

Gamble on opicinumab looks unlikely to pay off.

X

Biogen eyeing big-selling biosimilars as MS drug fails

https://pharmaphorum.com/news/biosimilars-increasingly-important-biogen/

Healthcare systems aren’t making the most of biosimilars: pharma needs to support them

Healthcare systems aren’t making the most of biosimilars: pharma needs to support them

Biosimilars could save European and US healthcare systems billions – but more needs to be done to maximise

X

Healthcare systems aren’t making the most of biosimilars: pharma needs to support them

https://pharmaphorum.com/views-and-analysis/healthcare-systems-aren-t-making-the-most-of-biosimilars-pharma-needs-to-support-them/

Biosimilars could save US and EU $110bn by 2020 – report

Biosimilars could save US and EU $110bn by 2020 – report

Healthcare systems in the US and the five largest EU countries could save up to 98 billion euros

X

Biosimilars could save US and EU $110bn by 2020 – report

https://pharmaphorum.com/news/biosimilars-could-save-us-and-eu-110bn-by-2020-report/

US physicians favour biosimilars

US physicians favour biosimilars

As the US FDA moves towards issuing final guidelines on biosimilars, recent research with specialists in five main

X

US physicians favour biosimilars

https://pharmaphorum.com/articles/us-physicians-favour-biosimilars/

«< 11 12 13 14 15 >

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com